iCAD Yönetim

Yönetim kriter kontrolleri 2/4

iCAD CEO'su Dana Brown, Mar2023 tarihinde atandı, in görev süresi 1.67 yıldır. in toplam yıllık tazminatı $ 849.05K olup, şirket hissesi ve opsiyonları dahil olmak üzere 37.1% maaş ve 62.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.15% ine doğrudan sahiptir ve bu hisseler $ 69.60K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.6 yıl ve 4.5 yıldır.

Anahtar bilgiler

Dana Brown

İcra Kurulu Başkanı

US$849.0k

Toplam tazminat

CEO maaş yüzdesi	37.1%
CEO görev süresi	1.7yrs
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	1.6yrs
Yönetim Kurulu ortalama görev süresi	4.5yrs

Son yönetim güncellemeleri

Recent updates

iCAD, Inc. (NASDAQ:ICAD) Stock Rockets 26% But Many Are Still Ignoring The Company

Aug 21

iCAD, Inc.'s (NASDAQ:ICAD) P/S Still Appears To Be Reasonable

Jun 27

iCAD, Inc. (NASDAQ:ICAD) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Feb 29

CEO Tazminat Analizi

Dana Brown'un ücretlendirmesi iCAD'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$5m
Mar 31 2024	n/a	n/a	-US$5m
Dec 31 2023	US$849k	US$315k	-US$7m
Sep 30 2023	n/a	n/a	-US$9m
Jun 30 2023	n/a	n/a	-US$11m
Mar 31 2023	n/a	n/a	-US$9m
Dec 31 2022	US$121k	n/a	-US$10m

Tazminat ve Piyasa: Dana 'ın toplam tazminatı ($USD 849.05K ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 656.26K ).

Tazminat ve Kazançlar: Dana şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Dana Brown (59 yo)

1.7yrs

Görev süresi

US$849,047

Tazminat

Ms. Dana R. Brown was Independent Director of iCAD, Inc. from January 10, 2022 until January 2023 and serves as its Executive Chair from January 2023 and also serves as its President and Chief Executive Of...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Dana Brown	President	1.7yrs	US$849.05k	0.15% $ 69.6k
Eric Lonnqvist	Chief Financial Officer	1.6yrs	US$385.05k	0.0053% $ 2.4k
Jonathan Go	Chief Technology Officer	5.8yrs	US$406.56k	0.72% $ 328.4k
Michelle Strong	Chief Operations Officer	1.5yrs	Veri yok	Veri yok
Annette Heroux	Vice President of Administration	no data	US$177.53k	Veri yok
Brian Testa	Chief People Officer	3.4yrs	Veri yok	Veri yok
Bill Keyes	Senior VP of Global Sales Operations	1.8yrs	Veri yok	Veri yok
Vasu Avadhanula	Chief Product Officer	1.5yrs	Veri yok	Veri yok
Peter Graham	Senior VP of North American Sales	less than a year	Veri yok	Veri yok

1.6yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim: ICAD 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.6 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Dana Brown	President	2.8yrs	US$849.05k	0.15% $ 69.6k
Michael Doyle	Independent Director	less than a year	Veri yok	0% $ 0
Susan Wood	Independent Director	6.2yrs	US$90.96k	0.016% $ 7.2k
Andrew Sassine	Independent Director	8.9yrs	US$86.24k	4.55% $ 2.1m
Stamatia Destounis	Member of Medical Advisory Board	no data	Veri yok	Veri yok
Robert Nishikawa	Member of Medical Advisory Board	no data	Veri yok	Veri yok
Kathy Schilling	Member of Medical Advisory Board	no data	Veri yok	Veri yok
Emily Conant	Member of Medical Advisory Board	no data	Veri yok	Veri yok
Hedvig Hricak	Independent Director	less than a year	Veri yok	0% $ 0
Per Hall	Member of Medical Advisory Board	no data	Veri yok	Veri yok
Rakesh Patel	Independent Director	6.2yrs	US$82.17k	0.24% $ 108.3k
Linda Moy	Member of Medical Advisory Board	no data	Veri yok	Veri yok

4.5yrs

Ortalama Görev Süresi

60.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ICAD 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.5 yıldır).

iCAD Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

iCAD, Inc., Annual General Meeting, Jun 13, 2024

iCAD, Inc. Appoints Michael John Doyle to its Board of Directors

iCAD, Inc. Expands Executive Sales Leadership Team as Business Grows

Executive Chair recently bought US$52k worth of stock

iCAD, Inc. Appoints Bill Keyes as Senior Vice President, US Commercial Sales, AI

iCAD, Inc. Appoints Dana Brown as Executive Chair of the Board of Directors

Recent updates

iCAD, Inc. to Report Q3, 2024 Results on Nov 13, 2024

iCAD Highlights Global Availability of ProFound Cloud and International Expansion Milestones at JFR 2024

iCAD, Inc. (NASDAQ:ICAD) Stock Rockets 26% But Many Are Still Ignoring The Company

Consensus EPS estimates fall by 18%, revenue upgraded

New major risk - Revenue and earnings growth

iCAD, Inc. to Report Q2, 2024 Results on Aug 13, 2024

iCAD, Inc.'s (NASDAQ:ICAD) P/S Still Appears To Be Reasonable

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2026

iCAD, Inc. to Report Q1, 2024 Results on May 15, 2024

iCAD, Inc., Annual General Meeting, Jun 13, 2024

No longer forecast to breakeven

iCAD, Inc. Showcases New Profound Cloud, Enhanced Profound Detection Workstation Features at SBI Annual Symposium

iCAD, Inc. Announces Commercial Availability of ProFound Cloud

Consensus revenue estimates fall by 12%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Share price stability

iCAD, Inc. (NASDAQ:ICAD) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

iCAD, Inc. to Report Q4, 2023 Results on Mar 12, 2024

iCAD, Inc. Appoints Michael John Doyle to its Board of Directors

Forecast to breakeven in 2026

iCAD, Inc. Expands Executive Sales Leadership Team as Business Grows

iCAD, Inc. to Present New Studies Valuating its Artificial Intelligence Powered ProFound Breast Health Suite

iCAD, Inc. to Present New Studies Valuating its Artificial Intelligence Powered ProFound Breast Health Suite

New minor risk - Shareholder dilution

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates decrease by 16%

iCAD, Inc. to Report Q3, 2023 Results on Nov 13, 2023

New minor risk - Profitability

Elekta AB (publ) (OM:EKTA B) agreed to acquire Xoft, Inc. from iCAD, Inc. (NasdaqCM:ICAD).

We're Hopeful That iCAD (NASDAQ:ICAD) Will Use Its Cash Wisely

Consensus EPS estimates upgraded to US$0.37 loss, revenue downgraded

Health Canada Grants Device License for iCAD's Profound Risk 2.0, Revolutionizing Breast Cancer Risk Via A 1-2 Year Assessment

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

iCAD, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Price target increased by 10% to US$4.88

We Think iCAD (NASDAQ:ICAD) Needs To Drive Business Growth Carefully

Consensus EPS estimates fall by 22%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Executive Chair recently bought US$52k worth of stock

No longer forecast to breakeven

Price target decreased by 38% to US$5.08

Will iCAD (NASDAQ:ICAD) Spend Its Cash Wisely?

iCAD, Inc. Appoints Bill Keyes as Senior Vice President, US Commercial Sales, AI

iCAD, Inc. Appoints Dana Brown as Executive Chair of the Board of Directors

iCAD, Inc. Announces Nathaniel Dalton's Resignation from His Position as A Member of the Board

Consensus revenue estimates fall by 11%

Price target decreased to US$8.17

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Is iCAD (NASDAQ:ICAD) In A Good Position To Invest In Growth?

iCAD, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Consensus revenue estimates fall by 15%

Forecast to breakeven in 2024

iCAD, Inc. to Report Q2, 2022 Results on Aug 10, 2022

iCAD, Inc.(NasdaqCM:ICAD) dropped from Russell 2000 Dynamic Index

Companies Like iCAD (NASDAQ:ICAD) Are In A Position To Invest In Growth

iCad, Inc. Announces CFO Changes

Icad, Inc. Announces Chief Financial Officer Changes

Icad, Inc. Announces That New Research Supporting Profound Ai for Digital Breast Tomosynthesis

iCAD, Inc. Announces Promising Clinical Research Supporting Profound Ai(R) Risk for Digital Breast Tomosynthesis

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

iCAD, Inc., Annual General Meeting, Jun 17, 2022

iCAD Announces Significant Commercial Momentum for ProFound AI Among Customers Equipped with the Provider of 3D Mammography Systems

No longer forecast to breakeven

iCAD, Inc. Announces Board Changes

iCAD, Inc. Announces Additional Patients Treated Under GLIOX Trial and Continued Global Momentum for Xoft Intraoperative Radiation Therapy for Brain, Rectal, Head and Neck Tumor Treatment

Consensus EPS estimates fall by 71%

Full year 2021 earnings: EPS exceeds analyst expectations